Pregnancy Related Clinical Trial
— NoviiOfficial title:
Evaluation of the Novii External Fetal Monitoring Device: A Prospective, Randomized Comparison
Verified date | October 2017 |
Source | Intermountain Health Care, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will be conducted on women in labor. Fetal heart rate monitoring will be conducting using the Novii Fetal ECG/EMG system and comparing it to current standard of care external fetal heart rate and tocometry. These approaches will be compared with the respect to need for additional monitoring, amount of nursing intervention, cost and satisfaction of patients and healthcare providers.
Status | Completed |
Enrollment | 218 |
Est. completion date | June 28, 2017 |
Est. primary completion date | June 28, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Pregnant women = 18 years of age; gestational age = 37 weeks - Singleton pregnancy. - These women will be those presenting to Labor and Delivery for one of the following: - Rule out labor - Spontaneous labor - Induction of labor Exclusion Criteria: - Age < 18 years old; multiple gestation pregnancy; gestational age < 37 weeks - Fetal distress or vaginal bleeding prior to monitor placement - Previous cesarean section - Planned cesarean delivery. - Women who are enrolled in the study but have less than 1 hour of fetal heart rate monitoring after randomization will be excluded from analysis. |
Country | Name | City | State |
---|---|---|---|
United States | Intermountain Medical Center | Murray | Utah |
United States | McKay-Dee Hospital | Ogden | Utah |
United States | Utah Valley Hospital | Provo | Utah |
United States | LDS Hospital | Salt Lake City | Utah |
Lead Sponsor | Collaborator |
---|---|
Intermountain Health Care, Inc. | GE Healthcare |
United States,
Bakker PC, Colenbrander GJ, Verstraeten AA, Van Geijn HP. The quality of intrapartum fetal heart rate monitoring. Eur J Obstet Gynecol Reprod Biol. 2004 Sep 10;116(1):22-7. — View Citation
Cohen WR, Hayes-Gill B. Influence of maternal body mass index on accuracy and reliability of external fetal monitoring techniques. Acta Obstet Gynecol Scand. 2014 Jun;93(6):590-5. doi: 10.1111/aogs.12387. Epub 2014 Apr 30. — View Citation
Cohen WR, Ommani S, Hassan S, Mirza FG, Solomon M, Brown R, Schifrin BS, Himsworth JM, Hayes-Gill BR. Accuracy and reliability of fetal heart rate monitoring using maternal abdominal surface electrodes. Acta Obstet Gynecol Scand. 2012 Nov;91(11):1306-13. doi: 10.1111/j.1600-0412.2012.01533.x. Epub 2012 Oct 19. — View Citation
Dawes GS, Visser GH, Goodman JD, Redman CW. Numerical analysis of the human fetal heart rate: the quality of ultrasound records. Am J Obstet Gynecol. 1981 Sep 1;141(1):43-52. — View Citation
Rooth G, Huch A, Huch R (1987) FIGO news: guidelines for the use of fetal monitoring. Int J Gynaecol Obstet 25:159-167
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Amount of time in minutes with the interpretable fetal heart rate tracing during the course of labor. | Quality of the fetal heart rate for each minute of tracing will be assessed visually by 2 or more blinded reviewers. For the purpose of this study, uninterpretable fetal heart rate will be defined as continuous fetal heart rate data with one or more of the following: Data is missing for more than 75% of the minute of tracing Artifact is present for more than 25% of the minute of tracing Missing data or artifact prevents determination of baseline rate > 15 seconds of continuous missing tracing Missing data is not continuous but is sufficiently frequent that the one minute segment of tracing could not be used to determine baseline rate The total number of interpretable minutes of fetal heart tracing and the percentage of time with interpretable fetal heart tracing over the course of labor (Number of minutes with interpretable FHR/Total number of minutes in labor) will be calculated for each patient. |
Time of randomization until time of delivery (up to 48 hours) | |
Secondary | Quality and interpretability of the FHT in ten minute segments | a. Each 10 minute segment will be deemed to be interpretable if it meets all of the following criteria: i. Sufficient data are available to determine a baseline ii. Sufficient data are available to determine the variability of the tracing iii. Sufficient data are available to identify periodic changes in the tracing (e.g. accelerations, decelerations, etc) b. For each 10 minute segment that is called Uninterpretable, the reviewer will indicate the reason for this designation by selecting one of the following options: i. Poor signal quality due to missing data ii. Poor signal quality due to artifact iii. Adequate signal quality but intrinsic fetal heart rate makes interpretation impossible (e.g. marked variability, etc.) | Time of randomization until time of delivery (up to 48 hours) | |
Secondary | Number and quality of uterine contractions in each 10 minute segment: | The number of uterine contractions per segment will be recorded b. Signal quality (amount of missing data or artifact) will be recorded | Time of randomization until time of delivery (up to 48 hours) | |
Secondary | Number and quality of uterine contractions in each 10 minute segment: | Signal quality (amount of missing data or artifact) will be recorded | Time of randomization until time of delivery (up to 48 hours) | |
Secondary | Number of times fetal heart rate monitor requires adjusting: | Measured by recording the number of times the nurse must adjust the monitoring system to obtain interpretable tracing | Time of randomization until time of delivery (up to 48 hours) | |
Secondary | Number of times fetal heart rate monitor requires adjusting: | Number of times that hand holding of the monitor is required | Time of randomization until time of delivery (up to 48 hours) | |
Secondary | Need for additional monitoring devices such as change from Novii to standard monitoring devices or the use of intrauterine pressure catheter or fetal scalp electrode: | Need for additional monitoring devices will be determined by the clinical care team including attending physician and/or nurses based on clinical judgment | Time of randomization until time of delivery (up to 48 hours) | |
Secondary | Need for additional monitoring devices such as change from Novii to standard monitoring devices or the use of intrauterine pressure catheter or fetal scalp electrode will be recorded by clinical care team: | Reason 1: Poor signal quality - missing data Reason 2: Poor signal - artifact Reason 3: Need additional information (e.g. intrauterine pressure, etc.) Reason 4: Patient preference Reason 5: Provider preference | Time of randomization until time of delivery (up to 48 hours) | |
Secondary | Need for additional monitoring devices such as change from Novii to standard monitoring devices or the use of intrauterine pressure catheter or fetal scalp electrode will be recorded by clinical care team: | Reason 2: Poor signal - artifact Reason 3: Need additional information (e.g. intrauterine pressure, etc.) Reason 4: Patient preference Reason 5: Provider preference | Time of randomization until time of delivery (up to 48 hours) | |
Secondary | Need for additional monitoring devices such as change from Novii to standard monitoring devices or the use of intrauterine pressure catheter or fetal scalp electrode will be recorded by clinical care team: | Reason 3: Need additional information (e.g. intrauterine pressure, etc.) Reason 4: Patient preference Reason 5: Provider preference | Time of randomization until time of delivery (up to 48 hours) | |
Secondary | Need for additional monitoring devices such as change from Novii to standard monitoring devices or the use of intrauterine pressure catheter or fetal scalp electrode will be recorded by clinical care team: | Reason 4: Patient preference Reason 5: Provider preference | Time of randomization until time of delivery (up to 48 hours) | |
Secondary | Need for additional monitoring devices such as change from Novii to standard monitoring devices or the use of intrauterine pressure catheter or fetal scalp electrode will be recorded by clinical care team: | Reason 5: Provider preference | Time of randomization until time of delivery (up to 48 hours) | |
Secondary | Nursing time required for care: | We will record the amount of time that the nurses spend at the bedside to adjust the monitor b. Nurses will record the time and reasons that they enter the room | Time of randomization until time of delivery (up to 48 hours) | |
Secondary | Nursing time required for care: | Nurses will record the time and reasons that they enter the room | Time of randomization until time of delivery (up to 48 hours) | |
Secondary | Overall cost of care: | Total charge for care from admission to Labor and Delivery to transfer to postpartum care will be recorded for all patients | Hospitalization for labor, delivery, and recovery - 2-4 days | |
Secondary | Overall cost of care: | Delivery type and indication | Hospitalization for labor, delivery, and recovery - 2-4 days | |
Secondary | Maternal outcomes - Length of labor | Length of labor recorded | Hospitalization for labor, delivery, and recovery - 2-4 days | |
Secondary | Maternal outcomes - Delivery type | Type of delivery recorded (e.g., vaginal, cesarean section, etc.) | Hospitalization for labor, delivery, and recovery - 2-4 days | |
Secondary | Maternal outcomes - Indication for forceps/vacuum extraction or cesarean section, if performed | Clinical indication for forceps/vacuum extraction or cesarean section delivery | Hospitalization for labor, delivery, and recovery - 2-4 days | |
Secondary | Maternal outcomes - Estimated blood loss | Amount of blood loss (cc) recorded | Hospitalization for labor, delivery, and recovery - 2-4 days | |
Secondary | Maternal outcomes - Presence and severity of perineal lacerations | Lacerations and degree of laceration recorded | Hospitalization for labor, delivery, and recovery - 2-4 days | |
Secondary | Maternal outcomes - Intra-amniotic infection (clinical chorioamnionitis or triple I) | Infections documented | Hospitalization for labor, delivery, and recovery - 2-4 days | |
Secondary | Maternal outcomes - Presence of clinical endometritis | Endometritis diagnosis recorded | Hospitalization for labor, delivery, and recovery - 2-4 days | |
Secondary | Neonatal outcomes - APGAR Scores | APGAR scores recorded at 1 minute, 5 minutes, and 10 minutes | Hospitalization after delivery - 2-4 days | |
Secondary | Neonatal outcomes - Need for ICU Admission | Recorded NICU admission | Hospitalization after delivery - 2-4 days | |
Secondary | Neonatal outcomes - Birthweight | Infant birthweight (grams) | Hospitalization after delivery - 2-4 days | |
Secondary | Neonatal outcomes - Neonatal Sex | Neonatal sex recorded | Hospitalization after delivery - 2-4 days | |
Secondary | Patient and provider satisfaction - Patient Survey | Satisfaction survey completed by patient after delivery of infant | Up to 7 days after delivery | |
Secondary | Patient and provider satisfaction - Nurse Survey | Satisfaction survey completed by nurse attending labor/delivery after delivery of infant | Up to 7 days after delivery | |
Secondary | Patient and provider satisfaction - Attending Physician/Midwife Survey | Satisfaction survey completed by physician/midwife attending labor/delivery after delivery of infant | Up to 7 days after delivery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05017974 -
Research on Improving Sleep During Pregnancy
|
N/A | |
Completed |
NCT03284515 -
Vaccination In Pregnancy Gene Signature: VIP Signature Study
|
||
Recruiting |
NCT05969795 -
Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support
|
Phase 1 | |
Recruiting |
NCT06051201 -
Innovation for Small-scale Experiments: ReceptIVFity Test
|
N/A | |
Recruiting |
NCT04828382 -
Prospective Study of Pregnancy in Women With Cystic Fibrosis
|
||
Enrolling by invitation |
NCT04527926 -
STEPuP: Prenatal Provider Education and Training to Improve Medication-assisted Treatment Use During Pregnancy
|
N/A | |
Recruiting |
NCT04278651 -
Early Antenatal Support for Iron Deficiency Anemia
|
Phase 4 | |
Recruiting |
NCT04405700 -
Measuring Adverse Pregnancy and Newborn Congenital Outcomes
|
||
Recruiting |
NCT06258902 -
Odevixibat Pregnancy and Lactation Surveillance Program: A Study to Evaluate the Safety of Odevixibat During Pregnancy and/or Lactation
|
||
Completed |
NCT05487196 -
Effectiveness of Clonidine, Dexmedetomidine, and Fentanyl Adjuncts for Labor Epidural Analgesia
|
Phase 2 | |
Completed |
NCT03750968 -
Lutein & Zeaxanthin in Pregnancy - Carotenoid Supplementation During Pregnancy: Ocular and Systemic Effects
|
Phase 2 | |
Enrolling by invitation |
NCT06127277 -
Next4You: A Fully Mobile Relationships Based Program for Youth in Foster Care
|
N/A | |
Completed |
NCT05897697 -
Assessing Women's Preferences for Postpartum Thromboprophylaxis: the Prefer-Postpartum Study
|
||
Recruiting |
NCT05899101 -
The Impact of Opioid and Cannabis Exposure on Fetal Growth
|
||
Completed |
NCT05502510 -
Assessing the Effectiveness and Efficacy of the MyHealthyPregnancy Application
|
||
Completed |
NCT04296396 -
Opioid Prescription After Cesarean Trial
|
Phase 3 | |
Not yet recruiting |
NCT06069856 -
Multiple Micronutrient Supplementation (MMS) IFA- Iron Dose Acceptability Crossover Trial
|
Phase 3 | |
Not yet recruiting |
NCT06069869 -
Multiple Micronutrient Supplementation (MMS) Iron Dose Acceptability Crossover Trial
|
Phase 3 | |
Not yet recruiting |
NCT06163651 -
Evaluating a One-Year Version of the Parent-Child Assistance Program
|
N/A | |
Not yet recruiting |
NCT06079918 -
Multiple Micronutrient Supplementation for Maternal Anemia Prevention in Tanzania
|
Phase 3 |